Bausch + Lomb Corp's stock has seen a notable uptick, reflecting positive sentiment in the ophthalmology devices market.
Shares of Bausch + Lomb Corp (BLCO.TO) closed up 2.32% at CA$23.39 in the latest trading session, buoyed by optimism surrounding the ophthalmology devices market. The company is strategically positioned to capitalize on growing demand for innovative eye care solutions, particularly as the market is projected to expand significantly in the coming years.
Advertisement
Bausch + Lomb Corp
BLCO.TO
BLCO.TO
Bausch + Lomb Corp
WealthAwesomeAdvertisement
Market cap
$8.35B
52W high
$25.70
52W low
$19.36
1W change
+0.00%
Beta
0.55
Analyst Price Targets
Based on analyst covering BLCO
Wall Street analysts forecast BLCO stock price to rise 7.5% over the next 12 months.
Consensus
Moderately BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$25.18
+7.5% Upside
Current Price
C$23.43
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Advertisement
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on BLCO's historical volatility
30-Day Vol
33.3%
Annualized
90-Day Vol
29.2%
Annualized
Trend (90d)
+26.8%
Annualized drift
90d Mean
C$25.79
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$24.19 | C$21.57 – C$27.13 |
| 60 trading days | C$24.98 | C$21.23 – C$29.38 |
| 90 trading days | C$25.79 | C$21.14 – C$31.46 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Investors should keep an eye on Bausch + Lomb's developments in the ophthalmology sector, as increasing demand for advanced eye care solutions may drive further growth.
Market Cap: CA$8.09 Billion
Bausch + Lomb's market cap reflects its significant presence in the eye care industry, underscoring its potential for growth amidst increasing demand for ophthalmic solutions.
Bull case
The ophthalmology devices market is expected to grow from $56.61 billion in 2025 to $63.23 billion in 2026. This growth is driven by an aging population and a rise in eye disorders. Bausch + Lomb's recent acquisitions and focus on development position it well to take advantage of this trend.
Bear case
Despite the positive momentum, Bausch + Lomb has faced challenges in drug development, which could pose risks. For instance, the discontinuation of its glaucoma eye drop program highlights the unpredictability of pharmaceutical pipelines.
Market Growth in Ophthalmology
Advertisement
The ophthalmology devices market is projected to grow from $56.61 billion in 2025 to $63.23 billion in 2026, reflecting a compound annual growth rate (CAGR) of 11.7%. This growth is fueled by factors like an aging population, increased healthcare spending, and a rise in eye disorders. Bausch + Lomb's focus on innovation and expansion in this sector positions it favorably to capture market share.
Strategic Developments by Bausch + Lomb
Bausch + Lomb's recent acquisition of AcuFocus, Inc. enhances its surgical portfolio, especially in cataract and intraocular lens solutions. The company's diverse pipeline, which includes over 60 assets under development, shows its commitment to innovation and long-term growth. Despite recent setbacks with its glaucoma treatment, the company remains focused on advancing other promising candidates.
Investor Sentiment and Future Outlook
With shares rising, investor sentiment appears optimistic about Bausch + Lomb's potential in the growing ophthalmology market. However, investors should stay cautious of the risks tied to drug development and market fluctuations. Staying updated on the company's strategic moves and market trends will be crucial for making informed investment decisions.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
